- Home
- MITQ vs VRAX Comparison
MITQ vs VRAX Comparison
Compare MITQ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITQ | VRAX |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 1.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MITQ | VRAX |
|---|---|---|
| Price | $0.53 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 17.7K | ★ 5.6M |
| Earning Date | 05-14-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $20,139,000.00 | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.15 |
| 52 Week High | $1.66 | $1.34 |
Technical Indicators
Market Signals| Indicator | MITQ | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.09 | 45.08 |
| Support Level | $0.51 | N/A |
| Resistance Level | $0.64 | $0.25 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 69.23 | 23.38 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.